Evaluation of common gene expression patterns in the rat nervous system

Physiological Genomics

Volumn 16, Issue , 2004, Pages 1-7

  Kaiser, Sergio ^a   Nisenbaum, Laura K ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Brain cortex; GeneChip; Hippocampus; Lysergic acid; Methamphetamine; Microarray; Phencyclidine; Spinal cord; Traumatic injury

Indexed keywords

LYSERGIDE; METHAMPHETAMINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; PHENCYCLIDINE; PSYCHEDELIC AGENT; PSYCHOSTIMULANT AGENT; PSYCHOTROPIC AGENT;

ANIMAL TISSUE; BRAIN CORTEX; DNA MICROARRAY; DOWN REGULATION; GENE; GENE EXPRESSION; GENE SEQUENCE; HIPPOCAMPUS; INJURY; NERVOUS SYSTEM; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RAT; REVIEW; SPINAL CORD; UNINDEXED SEQUENCE;

ANIMALS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HALLUCINOGENS; HIPPOCAMPUS; LYSERGIC ACID DIETHYLAMIDE; NERVOUS SYSTEM; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHENCYCLIDINE; PREFRONTAL CORTEX; RATS; RECEPTORS, N-METHYL-D-ASPARTATE; RNA, MESSENGER; SPINAL CORD INJURIES; TELENCEPHALON;

ANIMALIA; EUKARYOTA;

EID: 1842483340     PISSN: 15312267     EISSN: None     Source Type: Journal    
DOI: 10.1152/physiolgenomics.00125.2003     Document Type: Review

References (33)

1. Aghajanian GK and Marek GJ. Serotonin model of schizophrenia: emerging role of glutamate mechanisms. Brain Res Brain Res Rev 31: 302-312, 2000.
2. Biello SM and Dafters RI. MDMA and fenfluramine alter the response of the circadian clock to a serotonin agonist in vitro. Brain Res 920: 202-209, 2001.
3. Boivin DB. Influence of sleep-wake and circadian rhythm disturbances in psychiatric disorders. J Psychiatry Neurosci 25: 446-458, 2000.
4. Breier A. Serotonin, schizophrenia and antipsychotic drug action. Schizophr Res 14: 187-202, 1995.
5. Bonney WE and Bunney BG. Molecular clock genes in man and lower animals: possible implications for circadian abnormalities in depression. Neuropsychopharmacology 22: 335-345, 2000.
6. 1C receptor agonist. J Pharmacol Exp Ther 258: 891-896, 1991.
7. Butler TL, Kassed CA, and Pennypacker KR. Signal transduction and neurosurvival in experimental models of brain injury. Brain Res Bull 59: 339-351, 2003.
8. de Saint HZ, Orosco M, Rouch C, Python A, and Nicolaidis S. Neuromodulation of the prefrontal cortex during sleep: a microdialysis study in rats. Neuroreport 11: 1619-1624, 2000.
9. Ferl GZ, Timmerman JM, and Witte ON. From the cover: extending the utility of gene profiling data by bridging microarray platforms. Proc Natl Acad Sci USA 100: 10585-10587.
10. Fibiger HC. The dopamine hypothesis of schizophrenia and mood disorders: contradictions and speculations. In: The Mesolimbic Dopamine System: from Motivation to Action, edited by Willner P and Scheel-Kruger J. London: Wiley, 1991, p. 615-637,
11. Franken P, Lopez-Molina L, Marcacci L, Schibler U, and Tafti M. The transcription factor DBP affects circadian sleep consolidation and rhythmic EEG activity. J Neurosci 20: 617-625, 2000.
12. Giacomelli S, Palmery M, Romanelli L, Cheng CY, and Silvestrini B. Lysergic acid diethylamide (LSD) is a partial agonist of D2 dopaminergic receptors and it potentiates dopamine-mediated prolactin secretion in lactotrophs in vitro. Life Sci 63: 215-222, 1998.
13. Keshaven MS, Reynolds CF, Miewald J III, and Montrose D. Slow-wave sleep deficits and outcome in schizophrenia and schizoaffective disorder. Acta Psychiatr Scand 91: 289-292, 1995.
14. Kovacevic R and Radulovacki M. Monoamine changes in the brain of cats during slow-wave sleep. Science 193: 1025-1027, 1976.
15. Krystal JH, Abi-Dargham A, Laruelle M, and Moghaddam B. Pharmacologic models of psychoses. In: Neurobiology of Mental Illness, edited by Charney DS, Nestler EJ, and Bunney BS. New York: Oxford University Press, 1999, p. 214-224.
16. Lauer CJ and Krieg JC. Slow-wave sleep and ventricular size: a comparative study in schizophrenia and major depression. Biol Psychiatry 44: 121-128, 1998.
17. Marek GJ, Wright RA, Schoepp DD, Monn JA, and Aghajanian GK. Physiological antagonism between 5-hydroxytryptamine(2A) and group II metabotropic glutamate receptors in prefrontal cortex. J Pharmacol Exp Ther 292: 76-87, 2000.
18. Matzilevich DA, Rall JM, Moore AN, Grill RJ, and Dash PK. High-density microarray analysis of hippocampal gene expression following experimental brain injury. J Neurosci Res 67: 646-663, 2002.
19. Moghaddam B, Adams B, Verma A, and Daly D. Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J Neurosci 17: 2921-2927, 1997.
20. Moghaddam B and Adams BW. Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. Science 281: 1349-1352, 1998.
21. Nichols CD and Sanders-Bush E. A single dose of lysergic acid diethylamide influences gene expression patterns within the mammalian brain. Neuropsychopharmacology 26: 634-642, 2002.
22. Niculescu AB, Segal DS III, Kuczenski R, Barrett T, Hauger RL, and Kelsoe JR. Identifying a series of candidate genes for mania and psychosis: a convergent functional genomics approach. Physiol Genomics 4: 83-91, 2000.
23. Nishino S, Mao J, Sampathkumaran R, and Shelton J. Increased dopaminergic transmission mediates the wake-promoting effects of CNS stimulants. Sleep Res Online 1: 49-61, 1998.
24. Pavlidis P and Noble WS. Analysis of strain and regional variation in gene expression in mouse brain. Genome Biol 2: RESEARCH0042, 2001.
25. Raghavendra R, V, Bowen KK, Dhodda VK, Song G, Franklin JL, Gavva NR, and Dempsey RJ. Gene expression analysis of spontaneously hypertensive rat cerebral cortex following transient focal cerebral ischemia. J Neurochem 83: 1072-1086, 2002.
26. Salin-Pascual RJ, Herrera-Estrella M, Galicia-Polo L, and Laurrabaquio MR. Olanzapine acute administration in schizophrenic patients increases delta sleep and sleep efficiency. Biol Psychiatry 46: 141-143, 1999.
27. Shoblock JR, Sullivan EB, Maisonneuve IM, and Glick SD. Neurochemical and behavioral differences between d-methamphetamine and d-amphetamine in rats. Psychopharmacology (Berl) 165: 359-369, 2003.
28. Song G, Cechvala C, Resnick DK, Dempsey RJ, and Rao VL. Gene-Chip analysis after acute spinal cord injury in rat. J Neurochem 79: 804-815, 2001.
29. Titeler M, Lyon RA, and Glennon RA. Radioligand binding evidence implicates the brain 5-HT2 receptor as a site of action for LSD and phenylisopropylamine hallucinogens. Psychopharmacology (Berl) 94: 213-216, 1988.
30. Van Reeth O and Turek FW. Stimulated activity mediates phase shifts in the hamster circadian clock induced by dark pulses or benzodiazepines. Nature 339: 49-51, 1989.
31. Watts VJ, Lawler CP, Fox DR, Neve KA, Nichols DE, and Mailman RB. LSD and structural analogs: pharmacological evaluation at D1 dopamine receptors. Psychopharmacology (Berl) 118: 401-409, 1995.
32. Yan L, Miyake S, and Okamura H. Distribution and circadian expression of dbp in SCN and extra-SCN areas in the mouse brain. J Neurosci Res 59: 291-295, 2000.
33. Yokota SI, Horikawa K, Akiyama M, Moriya T, Ebihara S, Komuro G, Ohta T, and Shibata S. Inhibitory action of brotizolam on circadian and light-induced per1 and per2 expression in the hamster suprachiasmatic nucleus. Br J Pharmacol 131: 1739-1747, 2000.